Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: A phase II study

Clinica Terapeutica

Volumn 150, Issue 1, 1999, Pages 11-15

  Gebbia, Vittorio ^a,e   Testa, A ^b   Borsellino, N ^c   Mauceri, G ^a   Varvara, F ^b   Tirrito, M L ^d   Sambataro, D ^a   Fallica, G ^a  

^a Centro Catanese di Oncologia   (Italy)

^b Clinica Macchiarella   (Italy)

^c Division of Medical Oncology   (Italy)

^d Clinica Torina   (Italy)

^e Centro Catanese di Oncologia   (Italy)

Author keywords

Chemotherapy; Gemcitabine; Metastases; Urothelial cancer

Indexed keywords

CISPLATIN; GEMCITABINE; METHOTREXATE;

ANALGESIA; ANEMIA; ARTICLE; BONE LESION; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; METASTASIS; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; THROMBOCYTOPENIA; UROGENITAL TRACT TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; HUMANS; NEOPLASM METASTASIS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0032894858     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. th Edition, Lippincott-Raven, Philapelphia, 1997
2. Moore MJ, Tannok IF : Chemotherapy of bladder cancer. Adv Urol 6: 127-156, 1993
3. Roth BJ : Palliative chemotherapy in advanced bladder cancer. Semin Oncol 22: 10-15, 1995 (suppl. 3)
4. Sternberg CN, Yagoda A,. Scher HI, et al.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403-407, 1985.
5. Sternberg CN, Yagoda A, Scher HI, et al. : Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448-2458, 1989
6. Loehrer PJ, Einhorn LH, Elson PJ, et al.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma : a cooperative group study. J Clin Oncol 10: 1066-1073, 1992
7. Logothetis CJ, Dexeus FH, Finn L, et al.: A prospective randomized trial comparing M-VAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 : 1050-1055, 1990
8. Gabrilove JL, Jakubowski A, Scher H, et al.: Effect of granulocyte colony - stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. New Engl J Med 318: 1414-1422, 1988
9. Moore MJ, Iscoe N, Tannok IF: A phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factor in patients with advanced transitional cell carcinoma. J Urol 150: 1131-1134, 1993
10. Logothetis C, Sella A, Amato R, et al.: Escalated MVAC +/-rhGMCSF in patients with advanced metastatic transitional cell carcinoma of the bladder. J Urol 149 : 318, 1993
11. Conner JP, Olsonn CA, Benson MC, et al.: Long term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of the urinary bladder: a cause for concern. Urology 34: 353-356, 1989
12. Igawa M, Kadena H, Usui T: Long term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in complete response patients. J Urol 151 : 454, 1994
13. Hertel LW, Boder GB, Kroin JS, et al.: Evaluation of anti-tumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res 50 : 4417-4422, 1990
14. Heinemann V, Hertel LW, Grindey GB, et al.: Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-B-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031, 1988
15. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
16. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53 : 447-451, 1958
17. Pollera CF, Ceribelli A, Crecco M, et al.: Weekly gemcitabine in advanced bladder cancer. A preliminary report from a phase I study. Ann Oncol 5 : 182-185, 1994
18. Stadler W, Kuzel T, Raghawan D, et al.: A phase II study of gemcitabine in the treatment of patients with advanced transitional cell carcinoma. Proc Am Soc Clin Oncol 14: 241, 1995 (Abstr. 1011)
19. Moore MJ, Tannok I, Ernst S, et al.: Gemcitabine demostrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 15: 250, 1996 (Abstr. 1012)